文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer.

作者信息

Zhou Lin, Liu Jia, Xue Jianxin, Xu Yong, Gong Youling, Deng Lei, Wang Shichao, Zhong Renming, Ding Zhenyu, Lu You

机构信息

Department of Thoracic Cancer, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.

出版信息

Radiat Oncol. 2014 May 21;9:117. doi: 10.1186/1748-717X-9-117.


DOI:10.1186/1748-717X-9-117
PMID:24884773
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4035738/
Abstract

BACKGROUND: Whole brain radiotherapy (WBRT) plus sequential focal radiation boost is a commonly used therapeutic strategy for patients with brain metastases. However, recent reports on WBRT plus simultaneous in-field boost (SIB) also showed promising outcomes. The objective of present study is to retrospectively evaluate the efficacy and toxicities of WBRT plus SIB with image guided intensity-modulated radiotherapy (IG-IMRT) for inoperable brain metastases of NSCLC. METHODS: Twenty-nine NSCLC patients with 87 inoperable brain metastases were included in this retrospective study. All patients received WBRT at a dose of 40 Gy/20 f, and SIB boost with IG-IMRT at a dose of 20 Gy/5 f concurrent with WBRT in the fourth week. Prior to each fraction of IG-IMRT boost, on-line positioning verification and correction were used to ensure that the set-up errors were within 2 mm by cone beam computed tomography in all patients. RESULTS: The one-year intracranial control rate, local brain failure rate, and distant brain failure rate were 62.9%, 13.8%, and 19.2%, respectively. The two-year intracranial control rate, local brain failure rate, and distant brain failure rate were 42.5%, 30.9%, and 36.4%, respectively. Both median intracranial progression-free survival and median survival were 10 months. Six-month, one-year, and two-year survival rates were 65.5%, 41.4%, and 13.8%, corresponding to 62.1%, 41.4%, and 10.3% of intracranial progression-free survival rates. Patients with Score Index for Radiosurgery in Brain Metastases (SIR) >5, number of intracranial lesions <3, and history of EGFR-TKI treatment had better survival. Three lesions (3.45%) demonstrated radiation necrosis after radiotherapy. Grades 2 and 3 cognitive impairment with grade 2 radiation leukoencephalopathy were observed in 4 (13.8%) and 4 (13.8%) patients. No dosimetric parameters were found to be associated with these late toxicities. Patients received EGFR-TKI treatment had higher incidence of grades 2-3 cognitive impairment with grade 2 leukoencephalopathy. CONCLUSIONS: WBRT plus SIB with IG-IMRT is a tolerable and effective treatment for NSCLC patients with inoperable brain metastases. However, the results of present study need to be examined by the prospective investigations.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80d5/4035738/70af29679b0f/1748-717X-9-117-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80d5/4035738/632622ad67a9/1748-717X-9-117-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80d5/4035738/19e1c9feeeaf/1748-717X-9-117-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80d5/4035738/70af29679b0f/1748-717X-9-117-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80d5/4035738/632622ad67a9/1748-717X-9-117-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80d5/4035738/19e1c9feeeaf/1748-717X-9-117-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80d5/4035738/70af29679b0f/1748-717X-9-117-3.jpg

相似文献

[1]
Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer.

Radiat Oncol. 2014-5-21

[2]
Whole-brain radiotherapy plus sequential or simultaneous integrated boost for the treatment of a limited number of brain metastases in non-small cell lung cancer: A single-institution study.

Cancer Med. 2020-1

[3]
Hippocampal avoidance with volumetric modulated arc therapy in melanoma brain metastases - the first Australian experience.

Radiat Oncol. 2013-3-18

[4]
Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.

Radiat Oncol. 2021-12-5

[5]
Sparing the hippocampus and the hypothalamic- pituitary region during whole brain radiotherapy: a volumetric modulated arc therapy planning study.

BMC Cancer. 2020-6-30

[6]
Chemoradiotherapy by intensity-modulated radiation therapy with simultaneous integrated boost in locally advanced or oligometastatic non-small-cell lung cancer-a two center experience.

Strahlenther Onkol. 2021-5

[7]
Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1-3 cerebral metastases.

Radiat Oncol. 2014-5-2

[8]
Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study.

Radiat Oncol. 2019-6-13

[9]
Adding simultaneous integrated boost to whole brain radiation therapy improved intracranial tumour control and minimize radiation-induced brain injury risk for the treatment of brain metastases.

BMC Cancer. 2023-12-16

[10]
Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study.

Oncotarget. 2017-7-25

引用本文的文献

[1]
Adding simultaneous integrated boost to whole brain radiation therapy improved intracranial tumour control and minimize radiation-induced brain injury risk for the treatment of brain metastases.

BMC Cancer. 2023-12-16

[2]
Application of piecewise VMAT technique to whole-brain radiotherapy with simultaneous integrated boost for multiple metastases.

Radiat Oncol. 2022-5-7

[3]
Modern Radiation Therapy for the Management of Brain Metastases From Non-Small Cell Lung Cancer: Current Approaches and Future Directions.

Front Oncol. 2021-11-2

[4]
Whole-Brain Radiation Therapy With Simultaneous Integrated Boost Versus Whole-Brain Radiation Therapy Plus Stereotactic Radiosurgery for the Treatment of Brain Metastasis From Lung Cancer.

Front Oncol. 2021-3-5

[5]
Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis.

BMC Cancer. 2019-11-14

[6]
Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis.

Cancer Manag Res. 2019-5-8

[7]
Survival and quality of life after whole brain radiotherapy with 3D conformal boost in the treatment of brain metastases.

Med Pharm Rep. 2019-1

[8]
Dosimetric evaluation of four whole brain radiation therapy approaches with hippocampus and inner ear avoidance and simultaneous integrated boost for limited brain metastases.

Radiat Oncol. 2019-3-15

[9]
EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.

CNS Drugs. 2017-9

[10]
[Whole Brain Irradiation and Hypo-fractionation Radiotherapy for the Metastases in Non-small Cell Lung Cancer].

Zhongguo Fei Ai Za Zhi. 2016-4-20

本文引用的文献

[1]
A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer.

Clin Cancer Res. 2013-7-29

[2]
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.

J Clin Oncol. 2013-1-22

[3]
Image-guided positioning in intracranial non-invasive stereotactic radiosurgery for the treatment of brain metastasis.

Tumori. 2012

[4]
Hypofractionated stereotactic radiotherapy with or without whole-brain radiotherapy for patients with newly diagnosed brain metastases from non-small cell lung cancer.

J Neurosurg. 2012-12

[5]
Testing different brain metastasis grading systems in stereotactic radiosurgery: Radiation Therapy Oncology Group's RPA, SIR, BSBM, GPA, and modified RPA.

J Neurosurg. 2012-12

[6]
EGFR mutation status in brain metastases of non-small cell lung carcinoma.

J Neurooncol. 2012-10-20

[7]
Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.

Asian Pac J Cancer Prev. 2012

[8]
Hypofractionated frameless stereotactic intensity-modulated radiotherapy with whole brain radiotherapy for the treatment of 1-3 brain metastases.

Neurol Sci. 2012-4-24

[9]
Cone-beam computed tomography in hypofractionated stereotactic radiotherapy for brain metastases.

Radiat Oncol. 2012-4-1

[10]
A phase II multi-institutional study assessing simultaneous in-field boost helical tomotherapy for 1-3 brain metastases.

Radiat Oncol. 2012-3-21

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索